Targeting TGF-β Signaling for Therapeutic Gain

Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells

(2016) Kazuhito Naka et al.   CANCER SCIENCE

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

(2016) Maia Vinogradova et al.   Nature Chemical Biology

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

(2016) Alba A. Brandes et al.   NEURO-ONCOLOGY

Management and Prevention of Breast Cancer After Radiation to the Chest for Childhood, Adolescent, and Young Adulthood Malignancy

(2015) Eva Koo et al.   ANNALS OF SURGICAL ONCOLOGY

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

(2015) Yutaka Fujiwara et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

(2015) Mario E. Lacouture et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

(2015) Claire Vanpouille-Box et al.   CANCER RESEARCH

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

(2015) Naoki Oshimori et al.   CELL

TRAF6 promotes TGFβ-induced invasion and cell-cycle regulation via Lys63-linked polyubiquitination of Lys178 in TGFβ type I receptor

(2015) Reshma Sundar et al.   CELL CYCLE

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

(2015) G. Giaccone et al.   EUROPEAN JOURNAL OF CANCER

Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time

(2015) Mi Zhou et al.   INTERNATIONAL JOURNAL OF CANCER

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

(2015) Lisa M. Rice et al.   JOURNAL OF CLINICAL INVESTIGATION

TGF-  Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET

(2015) M. W. den Hollander et al.   JOURNAL OF NUCLEAR MEDICINE

Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms

(2015) Daniel Bedinger et al.   mAbs

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

Preclinical Study of Novel Gene Silencer Pyrrole-Imidazole Polyamide Targeting Human TGF-β1 Promoter for Hypertrophic Scars in a Common Marmoset Primate Model

(2015) Jun Igarashi et al.   PLoS One

Structure of bone morphogenetic protein 9 procomplex

(2015) Li-Zhi Mi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

ACVR1 R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A

(2015) Sarah J. Hatsell et al.   Science Translational Medicine

Coupling the modules of EMT and stemness: A tunable ‘stemness window’ model

(2015) Mohit Kumar Jolly et al.   Oncotarget

STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade

(2015) Todd A. Triplett et al.   Cancer Immunology Research

Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity

(2015) Kevin Van der Jeught et al.   Oncotarget

Integrin  v 6 Promotes an Osteolytic Program in Cancer Cells by Upregulating MMP2

(2014) A. Dutta et al.   CANCER RESEARCH

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

(2014) Richard J. Kovacs et al.   Cardiovascular Toxicology

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

(2014) Jordi Rodon et al.   CLINICAL CANCER RESEARCH

Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking  V 8-TGF  signaling in the brain

(2014) T. D. Arnold et al.   DEVELOPMENT

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

(2014) Saar Gill et al.   IMMUNOLOGICAL REVIEWS

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

(2014) ALLEN COHN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

(2014) Jordi Rodón et al.   INVESTIGATIONAL NEW DRUGS

Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent

(2014) Cheng Hua Jin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combined targeting of TGF-β1 and integrin β3 impairs lymph node metastasis in a mouse model of non-small-cell lung cancer

(2014) Elizabeth Salvo et al.   Molecular Cancer

EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis

(2014) J. Y. Son et al.   MOLECULAR CANCER THERAPEUTICS

Potential approaches to reverse or repair renal fibrosis

(2014) Desiree Tampe et al.   Nature Reviews Nephrology

Structural determinants of integrin β-subunit specificity for latent TGF-β

(2014) Xianchi Dong et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

(2014) John C. Morris et al.   PLoS One

Genetic variants of Adam17 differentially regulate TGF  signaling to modify vascular pathology in mice and humans

(2014) K. Kawasaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TRAF6 Stimulates the Tumor-Promoting Effects of TGF  Type I Receptor Through Polyubiquitination and Activation of Presenilin 1

(2014) S. K. Gudey et al.   Science Signaling

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

(2013) Ivelina Gueorguieva et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Activin receptor inhibition by Smad2 regulates Drosophila wing disc patterning through BMP-response elements

(2013) A. J. Peterson et al.   DEVELOPMENT

Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes

(2013) Jeong-Hwan Yoon et al.   EMBO Molecular Medicine

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Multiple Self-Healing Squamous Epithelioma (MSSE): Rare Variants in an Adjacent Region of Chromosome 9q22.3 to Known TGFBR1 Mutations Suggest a Digenic or Multilocus Etiology

(2013) Hio Chung Kang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling

(2013) Paloma Bragado et al.   NATURE CELL BIOLOGY

Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs

(2013) Neil C Henderson et al.   NATURE MEDICINE

Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma

(2012) Zhiming Dong et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Abstract 1: Mcl-1 downregulation plays a crucial role in the synergistic anticancer activities between PI-3 kinase inhibitors and histone deacetylase inhibitors in primary NSCLC tumorsin vitroandin vivo

(2012) Hao Zhang et al.   CANCER RESEARCH

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

(2012) Sidong Huang et al.   CELL

Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade

(2012) Makiko Fujii et al.   CELL CYCLE

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Tumour promoting functions of TGF-  in CML-initiating cells

(2012) K. Miyazono   JOURNAL OF BIOCHEMISTRY

TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth

(2012) Makiko Fujii et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Transforming Growth Factor   Inhibits Bone Morphogenetic Protein-Induced Transcription through Novel Phosphorylated Smad1/5-Smad3 Complexes

(2012) E. Gronroos et al.   MOLECULAR AND CELLULAR BIOLOGY

Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy

(2012) Jason Park et al.   NATURE MATERIALS

Targeting the TGFβ signalling pathway in disease

(2012) Rosemary J. Akhurst et al.   NATURE REVIEWS DRUG DISCOVERY

Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia

(2012) Michael Benzinou et al.   Nature Communications

The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

(2011) Kendra Garrison et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Blockade of TGF-  Signaling by the TGF R-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma

(2011) M. Zhang et al.   CANCER RESEARCH

Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer

(2011) Karl-Hermann Schlingensiepen et al.   CANCER SCIENCE

Transforming growth factor β (TGFβ)-induced apoptosis: The rise and fall of Bim

(2011) Sneha Ramesh et al.   CELL CYCLE

Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1

(2011) J. P. Arnault et al.   CLINICAL CANCER RESEARCH

TGF 1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo

(2011) F. Bouquet et al.   CLINICAL CANCER RESEARCH

TGF- 1-induced PI3K/Akt/NF- B/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts

(2011) X. Zhu et al.   JOURNAL OF BIOCHEMISTRY

Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?

(2011) Mario E. Lacouture et al.   JOURNAL OF CLINICAL ONCOLOGY

Transcriptional Inhibition of Hypertrophic Scars by a Gene Silencer, Pyrrole–Imidazole Polyamide, Targeting the TGF-β1 Promoter

(2011) Hisayo Washio et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Latent TGF-β structure and activation

(2011) Minlong Shi et al.   NATURE

Trabedersen to target transforming growth factor- : when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142)

(2011) W. Wick et al.   NEURO-ONCOLOGY

Convection-enhanced delivery of a transforming growth factor- 2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142)

(2011) M. C. Chamberlain   NEURO-ONCOLOGY

Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

(2011) Mark J. Anderton et al.   TOXICOLOGIC PATHOLOGY

TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma

(2010) Judit Anido et al.   CANCER CELL

Intravital Imaging Illuminates Transforming Growth Factor β Signaling Switches during Metastasis

(2010) Silvia Giampieri et al.   CANCER RESEARCH

Smad Signaling Is Required to Maintain Epigenetic Silencing during Breast Cancer Progression

(2010) P. Papageorgis et al.   CANCER RESEARCH

TGF- -RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases

(2010) K. S. Mohammad et al.   CANCER RESEARCH

Combination effect of a TGF-β receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice

(2010) Osamu Shinto et al.   CANCER SCIENCE

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Anti-Transforming Growth Factor   Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

(2010) Z. Zhong et al.   CLINICAL CANCER RESEARCH

Integrin–TGF-β crosstalk in fibrosis, cancer and wound healing

(2010) Coert Margadant et al.   EMBO REPORTS

Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter

(2010) Adèle Hannigan et al.   JOURNAL OF CLINICAL INVESTIGATION

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute

Transcriptional inhibition of progressive renal disease by gene silencing pyrrole–imidazole polyamide targeting of the transforming growth factor-β1 promoter

(2010) Hiroyuki Matsuda et al.   KIDNEY INTERNATIONAL

TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

(2010) Kazuhito Naka et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Expansion and maintenance of human embryonic stem cell–derived endothelial cells by TGFβ inhibition is Id1 dependent

(2010) Daylon James et al.   NATURE BIOTECHNOLOGY

Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

(2010) U. Bogdahn et al.   NEURO-ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells

(2010) S Ehata et al.   ONCOGENE

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth

(2010) Kyoko Takeuchi et al.   PLoS One

Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models

(2010) Abhik Bandyopadhyay et al.   PLoS One

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

(2010) R. B. Corcoran et al.   Science Signaling

Epithelial–mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic

(2009) Angeliki Voulgari et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

A Stiff Blow from the Stroma: Collagen Crosslinking Drives Tumor Progression

(2009) Mei Rosa Ng et al.   CANCER CELL

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN

(2009) Zvi G. Fridlender et al.   CANCER CELL

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

(2009) J Nemunaitis et al.   CANCER GENE THERAPY

ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration

(2009) Bridgette N. Ray et al.   CARCINOGENESIS

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

(2009) Kandice R. Levental et al.   CELL

Elevated Cutaneous Smad Activation Associates with Enhanced Skin Tumor Susceptibility in Organ Transplant Recipients

(2009) K. A. Harradine et al.   CLINICAL CANCER RESEARCH

Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial–mesenchymal transition

(2009) Carl-Henrik Heldin et al.   CURRENT OPINION IN CELL BIOLOGY

TGF-β3 and cancer: A review

(2009) H.G. Laverty et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Oncogene and tumour suppressor: the two faces of SnoN

(2009) Samy Lamouille et al.   EMBO JOURNAL

Membrane protein GARP is a receptor for latent TGF-β on the surface of activated human Treg

(2009) Julie Stockis et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Treatment of malignant gliomas with TGF-β2 antisense oligonucleotides

(2009) Peter Hau et al.   Expert Review of Anticancer Therapy

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

(2009) Christine A. Iacobuzio-Donahue et al.   JOURNAL OF CLINICAL ONCOLOGY

Transforming Growth Factor-βs and Mammary Gland Involution; Functional Roles and Implications for Cancer Progression

(2009) Kathleen C. Flanders et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Pretranscriptional Regulation of Tgf-β1 by PI Polyamide Prevents Scarring and Accelerates Wound Healing of the Cornea After Exposure to Alkali

(2009) Min Chen et al.   MOLECULAR THERAPY

GARP (LRRC32) is essential for the surface expression of latent TGF-  on platelets and activated FOXP3+ regulatory T cells

(2009) D. Q. Tran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody-Mediated Blockade of Integrin  v 6 Inhibits Tumor Progression In vivo by a Transforming Growth Factor- Regulated Mechanism

(2008) L. A. Koopman Van Aarsen et al.   CANCER RESEARCH

Methylation Silencing of Transforming Growth Factor-  Receptor Type II in Rat Prostate Cancers

(2008) S. Yamashita et al.   CANCER RESEARCH

Systemic Blockade of Transforming Growth Factor-  Signaling Augments the Efficacy of Immunogene Therapy

(2008) S. Kim et al.   CANCER RESEARCH

A pyrrole–imidazole polyamide targeting transforming growth factor-β1 inhibits restenosis and preserves endothelialization in the injured artery

(2008) En-Hui Yao et al.   CARDIOVASCULAR RESEARCH

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

TGF-β: A Master of All T Cell Trades

(2008) Ming O. Li et al.   CELL

Roles of TGFβ in metastasis

(2008) David Padua et al.   CELL RESEARCH

Transforming Growth Factor-  Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers

(2008) A. Wallace et al.   CLINICAL CANCER RESEARCH

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

(2008) Jeffrey A Engelman et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells

(2008) Emilia Fransvea et al.   HEPATOLOGY

Small Molecular Inhibitor of Transforming Growth Factor-β Protects Against Development of Radiation-Induced Lung Injury

(2008) Mitchell S. Anscher et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

New Response Criteria Proposed for Immunotherapies

(2008) Rabiya S. Tuma   JNCI-Journal of the National Cancer Institute

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner

(2008) Alessandro Sorrentino et al.   NATURE CELL BIOLOGY

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IKK  is a critical coregulator of a Smad4-independent TGF -Smad2/3 signaling pathway that controls keratinocyte differentiation

(2008) P. Descargues et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Germline Allele-Specific Expression of TGFBR1 Confers an Increased Risk of Colorectal Cancer

(2008) L. Valle et al.   SCIENCE

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

(2007) Lorea Bueno et al.   EUROPEAN JOURNAL OF CANCER

Progressive pulmonary fibrosis is mediated by TGF-β isoform 1 but not TGF-β3

(2007) Kjetil Ask et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY